Flatiron Health today announced its presence at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition happening from December 6-9, 2025, in Orlando, Florida. Flatiron's ...

CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

Updated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated ...

Mandy Lauw, MD, PhD, recently honored with first-ever Young EHA Award, advocates for bigger roles for early-career clinicians ...

Ascentage Pharma Group International ( ($HK:6855) ) has provided an update. Ascentage Pharma announced that it will present the latest results ...

Imugene Limited announced that its abstract on azer-cel, an allogeneic CD19 CAR T therapy, has been selected for oral presentation at the 67th American Society of Hematology Annual Meeting in Florida.

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the ...

BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...

Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...